Particle.news
Download on the App Store

Peru’s Drug Regulator Updates Paracetamol Labels After Rare Acidosis Reports

Regulators acted after an EMA alert linked prolonged therapeutic dosing with rare high‑anion‑gap metabolic acidosis.

Overview

  • Digemid updated the technical datasheets and patient inserts for all medicines containing paracetamol across Peru.
  • The revisions modify sections on contraindications, warnings and precautions, drug interactions, and adverse reactions.
  • Reported cases have chiefly involved patients with severe renal failure, sepsis, malnutrition, or chronic alcoholism during prolonged use.
  • Health professionals are advised to stop paracetamol immediately and monitor closely if signs of metabolic acidosis appear, particularly with extended therapy or when combined with flucloxacillin.
  • Warning signs include rapid deep breathing, severe respiratory difficulty, somnolence, nausea, and vomiting, and national data record one confirmed case and four compatible reports among 1,838 submissions since 2010.